Abbott Laboratories (ABT) is overvalued and Medtronic Plc (MDT) is overvalued.
Both trade above our estimate of their intrinsic value. MDT is the closer of the two: -25%, against -48% for ABT.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 8.3% (average of 3 methods) values the shares at $70.00; the price of $103.69 is 48% above that value, and 78% of that value comes from beyond year five.
Leak Score 57/100 on 10 of 12 signals
Discounting its cash flows at 7.8% (average of 3 methods) values the shares at $72.41; the price of $90.77 is 25% above that value, and 80% of that value comes from beyond year five.
Leak Score 27/100 on 3 of 12 signals
| Metric | ABT | MDT |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Price | $103.69 | $90.77 |
| Intrinsic value | $70.00 | $72.41 |
| Margin of safety | -48% | -25% |
| Leak Score | 57/100 (10/12) | 27/100 (3/12) |
| Market cap | $179.4B | $116.1B |
| Revenue growth, 5 years | 5.1% | 3.8% |
| Operating margin | 16.4% | 19.9% |
| Net margin | 11.6% | 13.9% |
| Return on equity | 10.6% | 10.7% |
| Debt to equity | 0.64 | 0.56 |
| P/E | 33.5x | 22.4x |
| Forward P/E | 17.1x | 14.2x |
| P/B | 3.5x | 2.3x |
| Dividend yield | 2.5% | 3.1% |